1. Median overall survival increased by 3.2 months in the sacituzumab govitecan group compared to chemotherapy. 2. One fatal treatment-related ...
Click to read this study in The Lancet Oncology.
Click to read this study in the Journal of Clinical Oncology.
Click to read this study in JAMA.
Click to read this study in JAMA Network Open.
Click to read this study in Lancet Oncology.
Click to read this study in the Journal of Clinical Oncology.
Click here to read this study in JAMA Oncology.
Click to read this study in JAMA Oncology.
1. A five-year extension of anastrozole treatment was shown not to provide additional benefit compared to a two-year extension in ...
